" class="no-js "lang="en-US"> Daewoong Pharmaceutical - Medtech Alert
Friday, June 09, 2023

Breaking News

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Sir Richard Roberts Elected to National Academy of Sciences Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Daewoong Pharmaceutical | MTA

Daewoong Pharmaceutical

About Daewoong Pharmaceutical

Daewoong Pharmaceutical

Related Story

Diseases

 HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease | MTA

HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease

May 25 2023

HanAll Biopharma and Daewoong Pharmaceutical announced that they have entered into a co-development agreement with NurrOn […]

Clinical Trials

 Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes | MTA

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes

April 24 2023

The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]

Drug Development

 Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration | MTA

Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration

April 18 2023

Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open […]

News

 M8 Pharmaceuticals & Daewoong Pharmaceutical Sign Agreement | MTA

M8 Pharmaceuticals and Daewoong Pharmaceutical Sign Exclusive Licensing Agreement for Envlo™ for Brazil and Mexico

February 28 2023

M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 […]

Clinical Trials

 Daewoong Pharmaceutical Begins the First Administration of the Bersiporocin, a New Treatment for Idiopathic Pulmonary Fibrosis | MTA

Daewoong Pharmaceutical Begins the First Administration of the Bersiporocin, a New Treatment for Idiopathic Pulmonary Fibrosis

February 6 2023

The world’s first-in-class candidate substance against idiopathic pulmonary fibrosis, ‘Bersiposocin‘ (DWN12088), which is under the […]